Apollon Wealth Management LLC Sells 2,268 Shares of Hologic, Inc. (NASDAQ:HOLX)

Apollon Wealth Management LLC trimmed its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 42.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,126 shares of the medical equipment provider’s stock after selling 2,268 shares during the quarter. Apollon Wealth Management LLC’s holdings in Hologic were worth $255,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Empowered Funds LLC bought a new position in shares of Hologic in the first quarter valued at approximately $234,000. Seven Eight Capital LP raised its stake in shares of Hologic by 35.3% during the 1st quarter. Seven Eight Capital LP now owns 4,169 shares of the medical equipment provider’s stock worth $325,000 after purchasing an additional 1,088 shares during the period. Clearbridge Investments LLC boosted its holdings in shares of Hologic by 51.4% in the 1st quarter. Clearbridge Investments LLC now owns 518,596 shares of the medical equipment provider’s stock worth $40,430,000 after buying an additional 176,006 shares during the last quarter. UniSuper Management Pty Ltd grew its position in shares of Hologic by 435.7% during the 1st quarter. UniSuper Management Pty Ltd now owns 14,845 shares of the medical equipment provider’s stock valued at $1,157,000 after acquiring an additional 12,074 shares during the period. Finally, Bessemer Group Inc. grew its holdings in Hologic by 8.0% during the first quarter. Bessemer Group Inc. now owns 10,892 shares of the medical equipment provider’s stock valued at $848,000 after purchasing an additional 809 shares during the period. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Hologic Stock Up 0.2 %

HOLX stock opened at $78.79 on Tuesday. Hologic, Inc. has a 1-year low of $67.59 and a 1-year high of $84.67. The stock has a market cap of $18.30 billion, a price-to-earnings ratio of 23.66, a price-to-earnings-growth ratio of 2.48 and a beta of 0.98. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. The company’s 50 day moving average is $80.63 and its 200 day moving average is $78.28.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting the consensus estimate of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The firm had revenue of $987.90 million for the quarter, compared to analysts’ expectations of $978.25 million. During the same quarter last year, the company posted $0.89 EPS. The business’s quarterly revenue was up 4.5% on a year-over-year basis. Sell-side analysts predict that Hologic, Inc. will post 4.27 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on HOLX shares. JPMorgan Chase & Co. upped their price objective on shares of Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Raymond James raised their price objective on shares of Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a report on Tuesday, November 5th. StockNews.com upgraded shares of Hologic from a “hold” rating to a “buy” rating in a research note on Thursday, November 14th. Citigroup cut shares of Hologic from a “buy” rating to a “neutral” rating and lowered their target price for the company from $95.00 to $85.00 in a report on Tuesday, October 1st. Finally, Mizuho decreased their price objective on Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 5th. Four analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $89.91.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.